Autoimmune Skin Diseases and Survival Outcomes After Antineoplastic Treatment in Patients With Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patients with autoimmune skin diseases (ASDs) show improved cancer survival rates. This suggests a link between immune system activity in ASDs and better cancer prognosis, warranting further research into oncologic management.
Area Of Science
- Oncology
- Immunology
- Dermatology
Background
- Autoimmune skin diseases (ASDs) and cancer involve immune dysregulation.
- The impact of ASDs on cancer prognosis is not well understood.
Purpose Of The Study
- To investigate the association between ASDs and cancer prognosis.
- To evaluate survival outcomes in cancer patients with and without ASDs after antineoplastic treatment.
Main Methods
- Population-based cohort study using Taiwanese cancer and health insurance data (2019-2021).
- Included patients receiving chemotherapy, targeted therapy, or immunotherapy.
- Used inverse probability of treatment weighting (IPTW) and propensity score matching.
- Assessed all-cause and cancer-specific mortality using Cox and Fine-Gray models.
Main Results
- 197,895 patients analyzed; 26,008 with ASDs.
- Patients with ASDs had significantly better survival outcomes.
- IPTW-adjusted hazard ratio for all-cause mortality was 0.94 (95% CI, 0.92-0.96).
- Subdistribution hazard ratio for cancer-specific mortality was 0.94 (95% CI, 0.92-0.96).
- Alopecia areata and Sjögren syndrome were linked to lower mortality risk.
Conclusions
- Patients with ASDs demonstrate improved cancer survival.
- Suggests a potential immunological link between ASDs and cancer prognosis.
- Highlights the need for further research into underlying mechanisms and clinical implications.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...